Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"China Life Private Equity Investment","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GeneQuantum Raises Hundreds of Millions RMB in Series C Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"BrighGene Biomedical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gene Quantum and Brigh Gene Sign Agreement for Development of Antibody Immune Agonist Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Aimed Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Pyramid Bio","pharmaFlowCategory":"D","amount":"$1,020.0 million","upfrontCash":"$20.0 million","newsHeadline":"Pyramid Biosciences Expands Oncology Pipeline with In-Licensing of GQ1010, a Potential Best-in-class TROP2 Targeted Antibody Drug Conjugate (ADC), from GeneQuantum Healthcare","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"GeneQuantum Healthcare","pharmaFlowCategory":"D","amount":"$28.3 million","upfrontCash":"Undisclosed","newsHeadline":"Thousand Oaks Biologics and GeneQuantum Healthcare Signed A Strategic Partnership Agreement for ADC Drug Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Technology","graph2":"Approved"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Aimed Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Forge Stronger Partnership for Advanced ADC Development! GeneQuantum Healthcare and Aimed Bio Collaborate to Develop Five Innovative ADC Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"InxMed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GeneQuantum and InxMed have Reached a Technology Licensing Collaboration, Providing Strong Support for Innovative ADC Drug Research and Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Announces Strategic Collaboration with GeneQuantum Healthcare to Empower Early Discovery of Next-Generation Bioconjugates","therapeuticArea":"Technology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Technology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by GeneQuantum Healthcare

    Menu

    GeneQuantum Healthcare

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              GeneQuantum Healthcare

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nona Biosciences Announces Strategic Collaboration with GeneQuantum Healthcare to Empower Early Discovery of Next-Generation Bioconjugates

              Details:

              Under the collaboration, Nona Biosciences will integrate GeneQuantum's exclusive and innovative iLDC and iGDC platforms, with its Harbour Mice® platform and cutting-edge technologies, to advance the early discovery of next-generation bioconjugates.

              Lead Product(s): Bioconjugate

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Nona Biosciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              GeneQuantum Healthcare

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GeneQuantum and InxMed have Reached a Technology Licensing Collaboration, Providing Strong Support for Innovative ADC Drug Research and Development

              Details:

              Under the agreement, GeneQuantum will provide InxMed with its globally leading technologies in site-specific glycan conjugation, stable linker small molecule technology, and intelligent continuous conjugation production platform for developing innovative ADC drugs.

              Lead Product(s): Antibody-drug Conjugate

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: InxMed

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 17, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              GeneQuantum Healthcare

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Forge Stronger Partnership for Advanced ADC Development! GeneQuantum Healthcare and Aimed Bio Collaborate to Develop Five Innovative ADC Drugs

              Details:

              Under the collaboration, GeneQuantum and Aimed Bio aims to jointly develop up to five new antibody-drug conjugate drugs to address unmet clinical needs for patients with severe brain diseases.

              Lead Product(s): Antibody-drug Conjugate

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Aimed Bio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Expanded Collaboration July 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              GeneQuantum Healthcare

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Thousand Oaks Biologics and GeneQuantum Healthcare Signed A Strategic Partnership Agreement for ADC Drug Development

              Details:

              Under the partnership, GQ will leverage TOBio's expertise in CMC and commercial manufacturing to advance its pharmaceutical research on antibody-drug conjugate (ADC) products by using its innovative conjugation technology.

              Lead Product(s): Antibody-drug Conjugate

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: Thousand Oaks Biologics

              Deal Size: $28.3 million Upfront Cash: Undisclosed

              Deal Type: Partnership May 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              GeneQuantum Healthcare

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pyramid Biosciences Expands Oncology Pipeline with In-Licensing of GQ1010, a Potential Best-in-class TROP2 Targeted Antibody Drug Conjugate (ADC), from GeneQuantum Healthca...

              Details:

              Under the terms of the agreement, Pyramid Biosciences will develop and commercialize GQ1010, a potential best-in-class antibody drug conjugate (ADC) targeting TROP2, worldwide except for Greater China, using GeneQuantum's proprietary technology.

              Lead Product(s): GQ1010

              Therapeutic Area: Oncology Product Name: GQ1010

              Highest Development Status: IND Enabling Product Type: Large molecule

              Recipient: Pyramid Bio

              Deal Size: $1,020.0 million Upfront Cash: $20.0 million

              Deal Type: Licensing Agreement April 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              GeneQuantum Healthcare

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia

              Details:

              GQ1005, is a HER2 targeting ADC with an excellent bystander killing effect, and the stable linker technology have demonstrated the advantages through several IND enabled drug candidates.

              Lead Product(s): GQ1005

              Therapeutic Area: Oncology Product Name: GQ1005

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              GeneQuantum Healthcare

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate

              Details:

              The collaborating ADC is a first-in-class asset AMB302, with highly differentiated antibody against a unique target, a stable linker design and a novel payload with a strong by-stander killing effect.

              Lead Product(s): AMB302

              Therapeutic Area: Oncology Product Name: AMB302

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Aimed Bio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              GeneQuantum Healthcare

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Gene Quantum and Brigh Gene Sign Agreement for Development of Antibody Immune Agonist Conjugates

              Details:

              Both companies signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007. GQ1007 is a new type of antibody-drug conjugate which has achieves strong and lasting anti-tumor effect, overcomes the low response rate of PD-1 antibody in immunotherapy.

              Lead Product(s): GQ1007

              Therapeutic Area: Oncology Product Name: GQ1007

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: BrighGene Biomedical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration September 05, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              GeneQuantum Healthcare

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GeneQuantum Raises Hundreds of Millions RMB in Series C Funding

              Details:

              GQ1001 is an antibody drug conjugate (ADC) that is currently in global multi-center clinical trial development for treatment of HER2+ solid tumor. GQ1001 was synthesized by site-specific conjugation of toxin DM1 to trastuzumab.

              Lead Product(s): GQ1001

              Therapeutic Area: Oncology Product Name: GQ1001

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: China Life Private Equity Investment

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Series C Financing May 19, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY